Cumberland Pharmaceuticals (CPIX) Cost of Revenue (2016 - 2025)
Cumberland Pharmaceuticals (CPIX) has disclosed Cost of Revenue for 16 consecutive years, with $14.7 million as the latest value for Q4 2025.
- Quarterly Cost of Revenue rose 18.2% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Dec 2025, up 12.19% year-over-year, with the annual reading at $19.1 million for FY2025, 12.19% up from the prior year.
- Cost of Revenue hit $14.7 million in Q4 2025 for Cumberland Pharmaceuticals, up from $988760.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $14.7 million in Q4 2025 to a low of -$4.2 million in Q4 2022.
- Historically, Cost of Revenue has averaged $3.4 million across 5 years, with a median of $2.2 million in 2022.
- Biggest five-year swings in Cost of Revenue: plummeted 225.92% in 2022 and later skyrocketed 711.35% in 2024.
- Year by year, Cost of Revenue stood at $3.3 million in 2021, then tumbled by 225.92% to -$4.2 million in 2022, then surged by 136.75% to $1.5 million in 2023, then surged by 711.35% to $12.4 million in 2024, then rose by 18.2% to $14.7 million in 2025.
- Business Quant data shows Cost of Revenue for CPIX at $14.7 million in Q4 2025, $988760.0 in Q3 2025, and $2.0 million in Q2 2025.